Calcified Nodules in Drusen May Signal Progression of AMD
THURSDAY, Nov. 15, 2018 -- Calcified nodules in retinal drusen are linked to disease progression in patients with age-related macular degeneration (AMD), according to a study published in the Nov. 7 issue of Science Translational Medicine. Anna C.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 15, 2018 Category: Pharmaceuticals Source Type: news

Change Within Eye A Hint of Macular Degeneration?
The investigators discovered that calcifications in the retina -- the thin layer of tissue that lines the back of the eye -- raise the risk of advanced age-related macular degeneration (AMD). (Source: WebMD Health)
Source: WebMD Health - November 9, 2018 Category: Consumer Health News Source Type: news

Calcified Nodules Linked to AMD Progression Calcified Nodules Linked to AMD Progression
Calcified nodules in the retinas of patients with age-related macular degeneration are linked to the progression to advanced stage disease, a study has shown.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Calcified eye spots linked to progession of macular degeneration
The composition of calcified nodules in eyes have been linked to the progression of age-related macular degeneration in retinas, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 8, 2018 Category: Consumer Health News Source Type: news

Genentech touts data for refillable eye implant in wet-AMD trial
Roche‘s (OTC:RHHBY) Genentech touted additional positive data last week from a Phase II study of its Port Delivery System, a refillable eye implant designed to deliver ranibizumab to treat wet age-related macular degeneration. The company first reported top-line results from the Phase II Ladder study in July. The implant is intended to allow wet-AMD patients to go for months without needing to see an ophthalmologist for treatment; the current standard of care for wet-AMD patients involves monthly injections of therapy. Get the full story at our sister site, Drug Delivery Business News. The post Ge...
Source: Mass Device - October 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news

Metformin lowers age-related macular degeneration risk
Research, presented at the American Academy of Ophthalmology Meeting, suggests that patients with type-2 diabetes who use metformin lower their risk of developing age-related macular degeneration. Med Page Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 29, 2018 Category: Endocrinology Source Type: news

New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)
Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Media News)
Source: Roche Media News - October 29, 2018 Category: Pharmaceuticals Source Type: news

New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)
Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2018 Category: Pharmaceuticals Source Type: news

Fewer Injections With New Wet Macular Degeneration Therapies Fewer Injections With New Wet Macular Degeneration Therapies
New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, studies indicate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 28, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

LumiThera inks distro deal with Nikon ’ s Optos
LumiThera said today it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system intended for use in treating dry age-related macular degeneration. The deal will position Optos as the exclusive distributor of the device in 12 European countries, the Seattle-based company said. The device has already won CE Mark approval in the European Union, it added. “The distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area. Optos i...
Source: Mass Device - October 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Optical/Ophthalmic LumiThera Nikon Optos Inc. Source Type: news

Researchers develop new devices to test retinal cells
(Utah State University) Researchers at Utah State University have developed new devices to better understand the triggers of age-related macular degeneration (AMD) by mechanically stressing cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news

Drug Pipeline for Macular Degeneration in Focus at AAO Drug Pipeline for Macular Degeneration in Focus at AAO
Updates from phase 3 trials of VEGF inhibitors for neovascular age-related macular degeneration, and a novel genetic treatment, will be highlighted at the American Academy of Ophthalmology meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

The dangers of blue light from digital devices: It can harm your eye health
(Natural News) Is your cellphone damaging your eyes? New research has highlighted yet another pitfall of modern technology: It’s slowly making you blind. A study just published in Scientific Reports has uncovered a sordid truth: Constant exposure to blue light from beloved cellphones and other devices leads to age-related macular degeneration, one of the leading causes... (Source: NaturalNews.com)
Source: NaturalNews.com - October 18, 2018 Category: Consumer Health News Source Type: news

Eating leafy greens could help prevent macular degeneration
A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing early-stage age-related macular degeneration (AMD). Researchers at the Westmead Institute for Medical Research interviewed more than 2,000 Australian adults aged over 49 and followed them over a 15-year period. (Source: World Pharma News)
Source: World Pharma News - October 18, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Genentech kicks off Phase III trials for eye implant
Roche‘s (OTC:RHHBY) Genentech reported this week that the company launched three Phase III trials evaluating the Port drug-delivery implant in patients with wet age-related macular degeneration and diabetic macular edema. The device is a refillable eye implant designed to continuously release drugs over a period of several months. Get the full story at our sister site, Drug Delivery Business News. The post Genentech kicks off Phase III trials for eye implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news

Mediterranean Diet May Help Preserve Your Vision
The Mediterranean diet’s combination of fruits, legumes, whole grains, olive oil and fish seems to reduce the risk of late-stage age-related macular degeneration, a new study finds. (Source: WebMD Health)
Source: WebMD Health - October 4, 2018 Category: Consumer Health News Source Type: news

Adherence to Mediterranean Diet Linked to Lower Risk for AMD
THURSDAY, Oct. 4, 2018 -- Higher adherence to the Mediterranean diet (MeDi) is associated with a reduced risk for incident advanced age-related macular degeneration (AMD), according to a study recently published in Ophthalmology. B énédicte M. J.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2018 Category: Pharmaceuticals Source Type: news

A group of perfectly ordinary garden vegetables hold the key to preventing blindness
(Natural News) For many people, losing your eyesight is one of the strongest signs that you’re getting older. When you realize that you can no longer see as well as you once did, it’s easy to pass this off as a typical effect of aging, but the truth is that age-related macular degeneration, although common,... (Source: NaturalNews.com)
Source: NaturalNews.com - October 1, 2018 Category: Consumer Health News Source Type: news

NHS wins landmark High Court battle with two major drug firms
A judge rejected an action brought by Bayer and Novartis against 12 NHS clinical commissioning groups in north England relating to Avastin, an age-related macular degeneration drug. (Source: the Mail online | Health)
Source: the Mail online | Health - September 21, 2018 Category: Consumer Health News Source Type: news

Heidelberg Engineering wins FDA nod for upgraded eye imaging technology
Image of an eye using OCTA technology, courtesy of Heidelberg Engineering. The FDA has approved Heidelberg Engineering’s optical coherence tomography angiography module (OCTA), the company said today. The module is available for new and existing Spectralis upgradeable diagnostic imaging devices used to manage diabetic retinopathy, age-related macular degeneration and other macular diseases. OCTA is a noninvasive imaging technique that provides three-dimensional visualization of perfused ocular vasculature. Structural OCT uses light waves to take cross-section pictures of the retina, allowing the ophtha...
Source: Mass Device - September 20, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Diagnostics Food & Drug Administration (FDA) Imaging Optical/Ophthalmic Vision heidelbergengineering Source Type: news

Pixium Vision ’s novel Prima chip helps patients see the light
Pixium Vision said today that its Prima miniature wireless photovoltaic sub-retinal implant has been activated in the first five patients. The patients all have severe vision loss from atrophic dry age-related macular degeneration. They are enrolled in a three-year clinical study in France to evaluate the safety and function of the Prima chip in eliciting visual light perception, the company said in a statement. All five reported seeing useful light patterns in areas where they had had no remaining light perception. The current study patients will be taught how to interpret their new artificial central macular pe...
Source: Mass Device - August 30, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Implants Vision Pixium Vision Source Type: news

FDA Approves New Eylea (aflibercept) Injection Dosing Schedule in Wet Age-Related Macular Degeneration
TARRYTOWN, N.Y., Aug. 17, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Eylea (aflibercept)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 17, 2018 Category: Drugs & Pharmacology Source Type: news

Health Tip: Are You at Risk for Macular Degeneration?
-- Age-Related Macular Degeneration (AMD) is a leading cause of vision loss among people 50 and older, the U.S. National Eye Institute says. AMD damages the macula, a small spot near the center of the retina that's needed for sharp, central vision... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 15, 2018 Category: General Medicine Source Type: news

Three Eye Conditions Linked to Higher Alzheimer's Risk Three Eye Conditions Linked to Higher Alzheimer's Risk
More insight into the eye as a'window into the brain'comes from a study linking glaucoma, age-related macular degeneration, and diabetic retinopathy to a higher risk for Alzheimer's disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Study Links 3 Eye Diseases, Alzheimer's
Patients with age-related macular degeneration, diabetic retinopathy or glaucoma had a 40 to 50 percent greater risk of Alzheimer's disease than those without the eye conditions, the authors of a new study report. (Source: WebMD Health)
Source: WebMD Health - August 12, 2018 Category: Consumer Health News Source Type: news

Viagra could be a new miracle cure for blindness, scientists claim  
The anti-impotence drug may stop age-related macular degeneration.   This follows a two-year trial led at Columbia University in New York. The condition is the UK’s leading cause of blindness. (Source: the Mail online | Health)
Source: the Mail online | Health - August 11, 2018 Category: Consumer Health News Source Type: news

Eye conditions provide new lens screening for Alzheimer's disease
(University of Washington Health Sciences/UW Medicine) A study of 3,877 randomly selected patients found a significant link between three degenerative eye diseases -- age-related macular degeneration, diabetic retinopathy and glaucoma -- and Alzheimer' disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 8, 2018 Category: International Medicine & Public Health Source Type: news

Aerie expands drug-delivery tech deal with DSM Biomedical
Aerie Pharmaceuticals (NSDQ:AERI) said today that it expanded its drug-delivery R&D deal with DSM Biomedical. The two companies first joined forces in July last year to evaluate the sustained delivery of certain Aerie drugs using DSM’s polymer technology. Initially, the group was focused on developing drug-delivery tech for people with wet age-related macular degeneration and diabetic macular edema. Get the full story at our sister site, Drug Delivery Business News. The post Aerie expands drug-delivery tech deal with DSM Biomedical appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals DSM Biomedical Source Type: news

01.08.18: Not intended for U.S. and UK Media
Bayer receives approval of new treatment regimen for Eylea® in the EUNew treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or moremehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - August 1, 2018 Category: Pharmaceuticals Source Type: news

Bayer receives approval of new treatment regimen for Eylea ® in the EU (for specialized target groups only)
New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more (Source: Bayer Company News)
Source: Bayer Company News - August 1, 2018 Category: Pharmaceuticals Source Type: news

Apellis granted fast-track process for its signature treatment
Apellis Pharmaceuticals Inc. has gotten a thumbs up that will accelerate bringing one of its signature treatments to market. The U.S. Food and Drug Administration granted Fast Track status to Crestwood, Ky.-based Apellis' synthetic peptide APL-2 for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration. Cedric Francois, Apellis' founder and CEO, said in a news release that the designation by the FDA is an important recognition that shows the drug's importance,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 27, 2018 Category: Pharmaceuticals Authors: Chris Larson Source Type: news

Implant Poised to Transform Macular Degeneration Treatment Implant Poised to Transform Macular Degeneration Treatment
A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the highly anticipated LADDER trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration
Roche announced positive, top-line results from the LADDER study, the first successful phase II study of a long-acting delivery device for the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2018 Category: Pharmaceuticals Source Type: news

Genentech touts positive data for tiny, refillable eye implant
Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration. The refillable device, which is roughly the size of a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy. Get the full story at our sister site, Drug Delivery Business Ne...
Source: Mass Device - July 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news

OCT Angiography Predicts Exudation in Macular Degeneration OCT Angiography Predicts Exudation in Macular Degeneration
Optical coherence tomography (OCT) angiography can predict progression of age-related macular degeneration and identify which patients might benefit from prophylaxis, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

A Daily Orange May Reduce AMD Risk, Study Finds A Daily Orange May Reduce AMD Risk, Study Finds
People who regularly consumed oranges had a lower risk of developing age-related macular degeneration compared with those who did not eat oranges in a 15-year study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

New Geographic Atrophy Treatment Shows Promise New Geographic Atrophy Treatment Shows Promise
An experimental treatment slowed disease progression in patients with late-stage dry age-related macular degeneration, who have few treatment options.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 22, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Allergan, Molecular Partners eye drug meets main goal in two studies
Allergan Plc and Molecular Partners AG said on Thursday their treatment for age-related macular degeneration met the main goal in two late-stage studies. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Eating one orange a day could prevent a common cause of blindness
Researchers from the University of Sydney found that snacking on the popular citrus fruit reduces people's risk of developing age-related macular degeneration, which affects central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - July 14, 2018 Category: Consumer Health News Source Type: news

7 medtech stories we missed this week: July 13, 2018
[Image from unsplash.com]From Angiodroid receiving CE Mark approval to Masimo launching its vital signs app, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Angiodroid wins CE Mark for Angiopulse IABP Angiodroid announced in a July 11 press release that it has received CE Mark approval for its AngioPulse intra-aortic balloon pump device. The AngioPulse uses a new system for intra-aortic balloon pumps based on pressure regulation. It is designed for weaning solutions and is suitable for all types of patients needing intra-aortic balloon pump therapy. 2. Visura Technol...
Source: Mass Device - July 13, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Diagnostics Food & Drug Administration (FDA) Imaging Patient Monitoring Regulatory/Compliance Surgical Ultrasound angiodroid Healcerio Lipogems Masimo MedTech Oculocare ReDress Visura Technologies Source Type: news

Eating just one orange a day could prevent a common cause of blindness
Researchers from the University of Sydney found that snacking on the popular citrus fruit reduces people's risk of developing age-related macular degeneration, which affects central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - July 13, 2018 Category: Consumer Health News Source Type: news

Cilioretinal Artery May Protect Against AMD (CME/CE)
(MedPage Today) -- Findings could be clue to'wet'age-related macular degeneration etiology (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 9, 2018 Category: Primary Care Source Type: news

OptoVue wins FDA nod for AngioAnalytics tech
Ophthalmological-focused developer Optovue said yesterday it won FDA 510(k) clearance for its AngioAnalytics optical coherence tomography angiography blood vessel measurement tech designed to aid in managing disease that cause progressive blindness. The Fremont, Calif.-based company said it also won clearance for its 3D projection artifact removal software, designed to improve OCTA image quality to allow for accurate measurements and interpretation of its OCTA images. OptoVue touted that the newly cleared AngioAnalytics tech adds to its currently released AngioVue OCTA technology designed to provide high-resoluti...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Imaging Optical/Ophthalmic Regulatory/Compliance Optovue Source Type: news

More than 20 people go blind a month in the UK due to delayed and cancelled hospital appointments
More than half of the people in the UK suffering from treatable conditions such as wet age-related macular degeneration and glaucoma, have had an appointment postponed or cancelled at least once. (Source: the Mail online | Health)
Source: the Mail online | Health - June 6, 2018 Category: Consumer Health News Source Type: news

Mediterranean Diet Linked With Lower Incidence of Advanced AMD Mediterranean Diet Linked With Lower Incidence of Advanced AMD
People who eat a Mediterranean diet are less likely to develop advanced age-related macular degeneration (AMD).Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 5, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Better Outcomes of 2nd Eye With Choroidal Neovascularization After Anti-VEGF Treatment Better Outcomes of 2nd Eye With Choroidal Neovascularization After Anti-VEGF Treatment
Visual acuity outcomes after anti-vascular endothelial growth factor (anti-VEGF) treatment for choroidal neovascularization (CNV) are better in fellow eyes of previously treated patients with neovascular age-related macular degeneration (nvAMD), according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Bayer receives approval for Eylea ® in China (for specialized target groups only)
Eylea ® gains approval in China for the treatment of visual impairment due to neovascular (wet) age-related macular degeneration (Source: Bayer Company News)
Source: Bayer Company News - May 11, 2018 Category: Pharmaceuticals Source Type: news

Cochrane Reviews on vision screening and reading aids updated
The College of Optometrists, UK has funded two Cochrane Review updates in support of theCochrane Eyes and Vision (CEV) group based at the London School of Hygiene and Tropical Medicine (LSHTM). The global review updates were used to answer questions on the topics ofVision screening for correctable visual acuity deficits in school-age children and adolescents andReading aids for adults with low vision.The review updates produced the following key findings:Vision screeningThere are no studies comparing vision screening with no vision screening highlighting a gap in evidence.Vision screening with the provision of free spectac...
Source: Cochrane News and Events - April 30, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news